Literature DB >> 6422848

Outcomes and indications of corpus callosum section for intractable seizure control.

M Rayport, S M Ferguson, W S Corrie.   

Abstract

Callosotomy (CCS) was performed in 9 cases of rigorously classified drug-refractory epilepsy not eligible for focal cortical resection. Complete CCS was carried out in two stages in 8 patients. 1 case had an anterior CCS only. None of the 9 patients has become seizure free. In 7, seizure frequency has diminished by a factor of 3-60 for at least one seizure type. Drop attacks in 2 cases have ceased. Clinical seizure patterns appeared more helpful in predicting outcome than preoperative EEG and stereoelectroencephalographic studies. Complete CCS may result in prolonged behavioral disturbances in the areas of language, hemisphere competition and attention-memory sequencing with impact on the sphere of daily living.

Entities:  

Mesh:

Year:  1983        PMID: 6422848     DOI: 10.1159/000101241

Source DB:  PubMed          Journal:  Appl Neurophysiol


  4 in total

1.  Elimination of medically intractable epileptic drop attacks following endoscopic total corpus callosotomy in Rett syndrome.

Authors:  Keisuke Ueda; Sandeep Sood; Eishi Asano; Ajay Kumar; Aimee F Luat
Journal:  Childs Nerv Syst       Date:  2017-08-16       Impact factor: 1.475

2.  Corpus callosotomy in the treatment of secondary generalizing intractable epilepsy.

Authors:  Z H Rappaport; P Lerman
Journal:  Acta Neurochir (Wien)       Date:  1988       Impact factor: 2.216

3.  Callosotomy for the management of intractable non-focal epilepsy: a preliminary personal assessment.

Authors:  I Papo; A Quattrini; L Provinciali; F Rychlicki; A Paggi; M Del Pesce; A Ortenzi
Journal:  Acta Neurochir (Wien)       Date:  1989       Impact factor: 2.216

4.  Anterior corpus callosotomy in patients with drug-resistant epilepsy: Invasive EEG findings and seizure outcomes.

Authors:  Olga Taraschenko; Swetha Pedavally; Kaeli K Samson; Mark J Puccioni; Deepak Madhavan
Journal:  Epilepsy Behav Case Rep       Date:  2017-12-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.